Online inquiry

IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ857MR)

This product GTTS-WQ857MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PRLR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000949.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5618
UniProt ID P16471
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ857MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13901MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2176
GTTS-WQ3905MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ9617MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ7853MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ14344MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7716
GTTS-WQ12181MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ6052MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ10914MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW